RHYTHM PHARMACEUTICALS, INC. (RYTM) Q3 2025 10-Q Quarterly Report
RHYTHM PHARMACEUTICALS, INC. (RYTM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
RHYTHM PHARMACEUTICALS, INC. Q3 2025 10-Q Analysis
Risk Factors
- • New risk from July 2025 $188.7M follow-on public offering; impact on capital structure and dilution risk increased
- • RIFA royalty burden update: tiered royalties 11.5%-2.5% on net revenues up to $300M+, $34.9M paid through Sept 2025, limits cash flow flexibility
- • Regulatory risk: uncertain approvals for setmelanotide indications with Phase 3 EMANATE trial sub-studies and FDA/EMA acceptance variability
- • Operational risk: early commercialization stage for IMCIVREE in US, Canada, EU, UK; manufacturing scale-up and market acceptance remain uncertain
- • Financial risk: cash/resources $416.1M Sept 2025; prior $100M RIFA debt plus Convertible Preferred Stock $147.8M; risk of capital raising under challenging markets
RHYTHM PHARMACEUTICALS, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$51M
▲ +54.3% YoY▲ +5.8% QoQ
Net Income
-$53M
▼ -21.1% YoY▼ -13.4% QoQ
Operating Margin
-102.6%
▲ +2934bp YoY▼ -925bp QoQ
Net Margin
-103.1%
▲ +2822bp YoY▼ -699bp QoQ
ROE
-35.5%
Total Assets
$507M
EPS (Diluted)
$-0.82
▼ -12.3% YoY▼ -9.3% QoQ
Operating Cash Flow
-$27M
▼ -5.6% YoY▼ -14.2% QoQ
Source: XBRL data from RHYTHM PHARMACEUTICALS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on RHYTHM PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.